Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $42.25

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $44.20.

Several equities analysts recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, March 24th. HC Wainwright raised their target price on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Citizens Jmp assumed coverage on shares of Avalo Therapeutics in a research note on Monday. They set an “outperform” rating and a $52.00 target price for the company. Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, March 29th. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th.

Insider Buying and Selling at Avalo Therapeutics

In related news, insider Mittie Doyle sold 25,492 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at approximately $58,495.30. This trade represents a 87.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the completion of the transaction, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at $297,346.70. The trade was a 31.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 42,130 shares of company stock valued at $693,225 over the last ninety days. 3.03% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Velan Capital Investment Management LP grew its stake in shares of Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after buying an additional 43,000 shares in the last quarter. Patient Square Capital LP purchased a new position in shares of Avalo Therapeutics in the 3rd quarter worth $1,271,000. Cantor Fitzgerald L. P. purchased a new position in shares of Avalo Therapeutics in the 3rd quarter worth $1,083,000. Boothbay Fund Management LLC boosted its stake in shares of Avalo Therapeutics by 1,916.6% during the 3rd quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock worth $2,902,000 after purchasing an additional 216,976 shares during the period. Finally, Ally Bridge Group NY LLC purchased a new position in shares of Avalo Therapeutics during the 3rd quarter worth about $2,264,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $16.27 on Friday. The company has a market capitalization of $370.79 million, a price-to-earnings ratio of -2.84 and a beta of 0.93. Avalo Therapeutics has a one year low of $3.39 and a one year high of $20.72. The company’s fifty day moving average price is $15.55 and its 200-day moving average price is $16.07.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. Equities research analysts expect that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.